Patents by Inventor Robert Talbert
Robert Talbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230040283Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: ApplicationFiled: June 9, 2022Publication date: February 9, 2023Inventors: Robert O. WILLIAMS, III, Keith P. JOHNSTON, Prapasri SINSWAT, Jason T. MCCONVILLE, Robert TALBERT, Jay I. PETERS, Alan B. WATTS, True L. ROGERS
-
Patent number: 11382899Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: GrantFiled: March 6, 2019Date of Patent: July 12, 2022Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Robert O. Williams, III, Keith P. Johnston, Prapasri Sinswat, Jason T. McConville, Robert Talbert, Jay I. Peters, Alan B. Watts, True L. Rogers
-
Publication number: 20220194255Abstract: A vehicle includes a traction battery, a human-machine interface (HMI), and a controller. The controller responsive to detecting electric vehicle supply equipment (EVSE) utilizing multiple price tiers corresponding to multiple maximum charge powers, outputs a message indicating a charge price corresponding to the maximum charge power for each of the price tiers via the HMI. The controller also, responsive to receiving user input indicating an adjusted maximum charge power less that a default maximum charge power of the vehicle, sends the adjusted maximum charge power to the EVSE and permits charging from the EVSE at or below the adjusted maximum charge power.Type: ApplicationFiled: December 22, 2020Publication date: June 23, 2022Applicant: FORD GLOBAL TECHNOLOGIES, LLCInventors: William HARTNAGEL, Ahthavan Raja SURESHKUMAR, Justin Carmen CAMPANARO, Robert TALBERT, Ryan HUNT
-
Publication number: 20190269661Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: ApplicationFiled: March 6, 2019Publication date: September 5, 2019Inventors: Robert O. WILLIAMS, III, Keith P. JOHNSTON, Prapasri SINSWAT, Jason T. MCCONVILLE, Robert TALBERT, Jay I. PETERS, Alan B. WATTS, True L. ROGERS
-
Patent number: 10231955Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: GrantFiled: February 12, 2015Date of Patent: March 19, 2019Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Robert O. Williams, III, Keith P. Johnston, Prapasri Sinswat, Jason T. McConville, Robert Talbert, Jay I. Peters, Alan B. Watts, True L. Rogers
-
Patent number: 9724344Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.Type: GrantFiled: May 15, 2015Date of Patent: August 8, 2017Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: James E. Hitt, True L. Rogers, Brian D. Scherzer, Ian B. Gillespie, Paula C. Garcia, Nicholas S. Beck, Christopher J. Tucker, Timothy J. Young, David A. Hayes, Robert O. Williams, III, Keith P. Johnston, Jason T. McConville, Jay I. Peters, Robert Talbert, David S. Burgess
-
Publication number: 20170165238Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: ApplicationFiled: December 20, 2016Publication date: June 15, 2017Inventors: Robert O. WILLIAMS, III, Keith P. JOHNSTON, Prapasri SINSWAT, Jason T. MCCONVILLE, Robert TALBERT, Jay I. PETERS, Alan B. WATTS, True L. ROGERS
-
Publication number: 20150320740Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.Type: ApplicationFiled: May 15, 2015Publication date: November 12, 2015Inventors: James E. HITT, True L. ROGERS, Brian D. SCHERZER, Ian B. GILLESPIE, Paula C. GARCIA, Nicholas S. BECK, Christopher J. TUCKER, Timothy J. Young, David A. HAYES, Robert O. WILLIAMS, III, Keith P. JOHNSTON, Jason T. MCCONVILLE, Jay I. PETERS, Robert TALBERT, David S. BURGESS
-
Publication number: 20150224062Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: ApplicationFiled: February 12, 2015Publication date: August 13, 2015Inventors: Robert O. WILLIAMS, III, Keith P. JOHNSTON, Prapasri SINSWAT, Jason T. MCCONVILLE, Robert TALBERT, Jay I. PETERS, Alan B. WATTS, True L. ROGERS
-
Patent number: 9061027Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.Type: GrantFiled: August 26, 2005Date of Patent: June 23, 2015Assignee: Board of Regents, the University of Texas SystemInventors: James E. Hitt, True L. Rogers, Ian B. Gillespie, Brian D. Scherzer, Paula C. Garcia, Nicholas S. Beck, Christopher J. Tucker, Timothy J. Young, David A. Hayes, Robert O. Williams, III, Keith P. Johnston, Jason T. McConville, Jay I. Peters, Robert Talbert, David Burgess
-
Patent number: 9044391Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: GrantFiled: January 10, 2008Date of Patent: June 2, 2015Assignee: Board of Regents, the University of Texas SystemInventors: Robert O. Williams, Keith P. Johnston, Prapasri Sinswat, Jason T. McConville, Robert Talbert, Jay I. Peters, Alan B. Watts, True L. Rogers
-
Publication number: 20100183721Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.Type: ApplicationFiled: January 10, 2008Publication date: July 22, 2010Applicant: Board of Regents, The University of Texas SystemInventors: Robert O. Williams, Keith P. Johnston, Prapasri Sinswat, Jason T. McConville, Robert Talbert, Jay I. Peters, Alan B. Watts, True L. Rogers
-
Publication number: 20070287675Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.Type: ApplicationFiled: August 26, 2005Publication date: December 13, 2007Applicants: THE DOW CHEMICAL COMPANY, BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEMInventors: James Hitt, True Rogers, Brian Scherzer, Ian Gillespie, Paula Garcia, Nicholas Beck, Christopher Tucker, Timothy Young, David Hayes, Robert Williams III, Keith Johnston, Jason McConville, Jay Peters, Robert Talbert, David Burgess